|
Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that goose the body's immune system to help it fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its lead candidate is Provenge, a therapeutic vaccine that targets prostate cancer. Dendreon is also working on a therapeutic vaccine called Neuvenge as a treatment for breast, colon, ovarian, and kidney cancers; and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs. Its partners for its antibody programs include Amgen and Genentech.
|
| | | Contact Information | |
Address: |
3005 1st Ave.
Seattle, WA 98121
| | Phone: | 206-256-4545 | | Fax: | 206-256-0571 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.10 M | | Revenue Growth (1 yr): | (-85.10%) | | Employees (2008): | 198 | | Employee Growth (1 yr): | 2.10% |
|
|
Key People
| | • |
Chairman:
Richard B. Brewer
| | • |
President, CEO, and Director:
Mitchell H. Gold
| | • |
SVP, CFO, and Treasurer:
Gregory T. (Greg) Schiffman
|
|
|
